Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / App Notes / 2022 / High-speed analysis for predictive identification of skin sensitization hazard

High-speed analysis for predictive identification of skin sensitization hazard

06/07/2022

Share

 

Skin sensitization tests evaluate the allergic reactivity of skin to chemical substances. For animal welfare reasons, non-animal alternative methods are being developed for these tests. Chemical substances can induce an inflammatory reaction if they bind to cysteine or lysine in epidermal proteins. International test guidelines for evaluating chemical substances, published by the Organisation for Economic Co-operation and Development (OECD), include the Direct Peptide Reactivity Assay (DPRA) and Amino Acid Derivative Reactivity Assay (ADRA) as alternative in chemico test methods based on the properties indicated above.

 

 

ADRA evaluates the binding characteristics of test substances using N-(2-(1-naphthyl)acetyl)-L-cysteine (NAC) or α-N-(2-(1- naphthyl)acetyl)-L-lysine (NAL), which are synthesized by inducing cysteine or lysine, respectively, to bind with naphthalene rings. ADRA sample solutions are analyzed at 1/100 of the concentration analyzed for DPRA. The presence of naphthalene rings enables detection at a 281 nm UV wavelength, where effects from any detection of contaminants are minimal.

The ADRA test method is specified in OECD TG 442C Appendix II, Annex 2. Annex 2 also specifies methods for system suitability testing and proficiency testing. Proficiency tests are performed to assess the technical proficiency of testing personnel and the given testing environment in terms of the binding characteristics of NAC and NAL (NAC and NAL percent depletion) with respect to ten types of test substances. The system suitability tests and proficiency tests described in this article were all performed using a Nexera XR high performance liquid chromatograph. The test results were within the specified ranges for all indicated substances.

High-speed conditions were also analyzed. Those results were no different from those obtained with the conditions specified by OECD.

 

 

>> Download Application Note as a PDF ​​​​​​​

 

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

HIVE scRNAseq Solution: A Case Study Demonstrating Sample Stability & Fragile Cell Recovery

January 4, 2022

Rapid Immunohistochemistry, Multiplex IF and Digital Pathology Workflow

January 4, 2022

Reduce Your Biomarker Optimization Time Burden with the LabSat® Research

January 31, 2022

Label-free quantification of RNA methylations using targeted mass spectrometry

April 5, 2022

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.